Genmab, AbbVie Say New Drug Combo Helps Lymphoma Patients Stay Cancer-Free Longer

MT newswire2026/10/05 19:50

03:50 PM EDT, 10/05/2026 (MT Newswires) -- Genmab (GMAB) and AbbVie (ABBV) said that adding their drug epcoritamab to a standard chemotherapy mix helped people with an aggressive form of blood cancer stay cancer-free longer than chemotherapy alone. The combination cut the risk of the cancer getting worse or the patient dying by 51% compared with standard treatment alone, the companies said Monday in a statement. Results were from a large study in newly diagnosed patients with diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma. The treatment paired epcoritamab with R-CHOP, a long-used chemotherapy regimen. The companies said the safety of the combination looked generally similar to what doctors already expect from each drug on its own. Because the treatment is still experimental, Genmab and AbbVie plan to meet with regulators around the world to discuss next steps. Genmab shares rose 11% in Monday trading, and AbbVie gained 1.3%. Price: 38.72, Change: +3.97, Percent Change: +11.41

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned

According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.

智通财经•2026/11/09 11:09

Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October

FXStreet•2026/11/09 10:57

The UK Financial Conduct Authority allows banks to submit applications for crypto-related businesses.

AiCoin•2026/11/09 10:45

SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries

A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.

华尔街见闻•2026/11/09 10:26